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Hepatocellular carcinoma (HCC) is common and one of the most aggressive of all human cancers. Recent studies have indi-
cated that miRNAs, a class of small noncoding RNAs that regulate gene expression post-transcriptionally, directly contribute 
to HCC by targeting many critical regulatory genes. Several miRNAs are involved in hepatitis B or hepatitis C virus replication 
and virus-induced changes, whereas others participate in multiple intracellular signaling pathways that modulate apoptosis, cell 
cycle checkpoints, and growth-factor-stimulated responses. When disturbed, these pathways appear to result in malignant 
transformation and ultimately HCC development. Recently, miRNAs circulating in the blood have acted as possible early di-
agnostic markers for HCC. These miRNA also could serve as indicators with respect to drug efficacy and be prognostic in 
HCC patients. Such biomarkers would assist stratification of HCC patients and help direct personalized therapy. Here, we 
summarize recent advances regarding the role of miRNAs in HCC development and progression. Our expectation is that these 
and ongoing studies will contribute to the understanding of the multiple roles of these small noncoding RNAs in liver tumor-
igenesis. 
miRNA, noncoding RNAs, hepatocellular carcinoma, cancer therapy 
 





Hepatocellular carcinoma (HCC) is a primary cancer of the 
liver; it ranks as the fifth most common malignant cancer 
and the third leading cause of cancer-related death world-
wide. In the United States, HCC accounts for almost all 
primary liver cancer cases with an incidence of 12.3 and 4.1 
cases per 100000 men and women, respectively. Unfortu-
nately, the incidence steadily increased from 1999 to 2008, 
according to surveillance conducted by the American Can-
cer Society in 2012 [1]. Chronic hepatitis B virus (HBV) 
and/or hepatitis C virus (HCV) infections resulting in he-
patic fibrosis and cirrhosis are the major risk factors for 
HCC, and we are currently seeing the long-term conse-
quence of extensive HCV transmission in the aging baby 
boomer populations in the United States. In China, HBV 
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infection is the major risk factor for HCC [2].  
To date, early diagnosis and treatment of HCC are dis-
appointing, as a consequence of the lack of effective and 
reliable screening methods. Two out of three HCC patients 
are only diagnosed at the time of advanced carcinoma [3]. 
In addition, HCC is largely insensitive to most chemothera-
peutic agents. New kinase inhibitors are potentially effec-
tive, and kinase inhibitors such as sorafenib may help pro-
long overall survival of patients with HCC and reduce dis-
ease recurrence after surgery or ablative therapies [4,5].  
Surgical resection and/or liver transplantation remain the 
best hope for curative treatment of HCC. However, only 
5%–15% of HCC patients are currently eligible for surgical 
intervention, based on evaluation of their liver function and 
tumor burden [6]. The Milan Criteria and University of Cal-
ifornia San Francisco Criteria have been used for selection 
of patients with HCC for liver resection or transplantation. 
However, the prognosis was poorer in the patients within 
these criteria. The reason may be the lack of effective 
methods for early diagnosis [7,8]. 
Recurrence and metastasis are common in patients who 
have undergone resection, with a postoperative 5-year survival 
rate of 30%–40% [9,10]. It is critical to diagnose HCC at an 
early stage, especially at a molecular level by contrasting ex-
pression profiles of crucial genes. Current clinical practice 
has primarily focused on protein-coding genes and their 
products as biomarkers such as -fetoprotein (AFP) [11]. 
However, these biomarkers fail to meet the needs for accu-
rate early diagnosis, prognosis and treatment stratification 
of HCC because of low sensitivity and specificity. Precise 
molecular mechanisms for the pathogenesis of HCC are 
urgently required, hence the requirement to define and then 
develop other novel molecular tools, for example, miRNAs, 
as biomarkers.  
miRNAs are endogenous small noncoding RNAs con-
sisting of 20–25 nucleotides (nt) that modulate gene expres-
sion by promoting mRNA degradation or repressing protein 
translation through sequence-specific interactions with the 
3′-untranslated region (UTR) of target mRNAs. miRNAs 
are known to play important roles in various physiological 
processes, for example, development, apoptosis, prolifera-
tion, and differentiation [12–19]. Deregulation of miRNA 
expression has also been implicated in many diseases in-
cluding cancer. Recent evidence has clearly demonstrated 
that, other than abnormal epigenetic modifications, dysreg-
ulation of miRNA expression may also contribute to aber-
rant activation of oncogenes, accompanied by inactivation 
of tumor suppressor genes [20–24].  
miRNAs could also interfere with HBV or HCV entry 
and replication in liver cells, as well as many other funda-
mental cellular processes such as determining cell cycle 
checkpoints, apoptosis and cell migration.  
In this review, we summarize the molecular mechanisms 
that underpin the roles of miRNAs in malignant transfor-
mation of liver cells, and their potential as biomarkers for 
HCC diagnosis and prognosis as well as effective targets for 
personalized treatment stratification.  
1  Human miRNAs as etiologic factors in HCC 
and the regulatory network  
1.1  Roles of miRNAs in virus-induced HCC  
Occurrence of HCC is often associated with chronic infec-
tion of HBV or HCV [25]. An HBV-encoded protein, HBx, 
is thought to play a major role in molecular pathogenesis of 
HBV-related HCC (HBV-HCC) [26,27] and migration of 
HCC cells. HBx-transgenic mice or HBx-transfected cells 
have been used as models for HBV-HCC [28–31], in which 
several miRNAs have been identified to be involved. miR-143 
is one of the most important miRNAs for HBV-HCC de-
velopment.  
Zhao et al. [32] have measured miR-143 expression lev-
els in p21-HBx transgenic mice at different ages during 
disease progression. The livers of 10-month-old mice lack-
ing neoplastic changes exhibited significantly reduced 
miR-143 levels. In contrast, at age 22 months, a two-fold 
increase in miR-143 expression was noted in liver tumors 
without lung metastasis, and a six-fold increase in those 
with lung metastasis. In humans, miR-143 was upregulated 
four-fold in HBV-HCC samples without lung metastasis, 
and eight-fold in HBV-HCC with lung metastasis [33]. 
However, minimal upregulation of miR-143 was observed 
in HBV-negative HCC, with or without metastasis.  
miR-143 overexpression in HBx-transfected cells signif-
icantly promotes cell migration with no substantial effect on 
cell proliferation or apoptosis [34]. Invasive capacity of 
these cells is robustly inhibited by cotransfection of anti-
sense oligonucleotides with miR-143. Furthermore, induc-
tion of miR-143 by intratumoral administration of 
p-miR-143 led to seven intrahepatic and two lung metasta-
ses in 15 p21-HBx transgenic mice [32]. In contrast, no 
metastasis was found in mice that received control miRNA 
vector. In vivo repression of miR-143 levels by injection of 
anti-miR-143 into these mice significantly blocked HCC 
development and metastases [35]. These data indicate that 
miR-143 eases HBx-controlled cell migration/invasion both 
in vitro and in vivo.  
miR-29a is also important in promoting HBV-HCC pro-
gression, and is dramatically upregulated in p21-HBx trans-
genic mice and in HepG2-X and H7402-X cell lines [36]. 
Overexpression of miR-29a enhances migration of HepG2 
cells [37]. Moreover, specific miR-29a inhibitors partially 
abolish HepG2-X cell migration without affecting HBx ex-
pression [38]. Phosphatase and tensin homolog (PTEN), a 
crucial tumor suppressor, has been identified as one of the 
target genes of miR-29a. Overexpression of miR-29a in 
hepatoma cells results in downregulation of PTEN and in-
creases serine phosphorylation of its downstream compo-
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nent, protein kinase B (Akt). PTEN and Akt are known to 
regulate many fundamental cellular functions including cell 
proliferation/growth, survival, migration, apoptosis, and 
metabolism [39,40]. Expression of PTEN leads to 
dephosphorylation of Akt and inhibition of cell growth and 
migration [41,42]. Overexpression of PTEN by transient 
transfection with pcDNA3-PTEN plasmid, or knockdown of 
Akt by siRNA can abolish the enhanced migration of 
HepG2 cells mediated by miR-29a. Thus, miR-29a can ease 
HBx-induced hepatoma cell migration by modulating PTEN 
and Akt. In addition, transfection with miR-29a increases 
mRNA levels of matrix metalloproteinase (MMP)-2 in HCC 
cell lines, which might also account for miR-29a-mediated 
cell migration [43]. However, miR-29a upregulation is not 
always observed in HCC patients. In 11 clinical HCC sam-
ples, only four showed upregulation of miR-29a.  
HCV infection is another independent risk factor for 
HCC. Infection with HCV results in increased oxidative 
stress in infected hepatocytes, causing further hepatocellular 
damage that could ultimately lead to malignant hepatocyte 
transformation [44,45]. miR-196 has been found to inhibit 
HCV expression and repress HCV-induced oxidative dam-
age. Transfection with miR-196 mimics significantly re-
duces HCV replication [46]. Two 6-nt sites within the HCV 
Con1 genome have been predicted to be complementary to 
a miR-196 region, implying that miR-196 inhibits HCV 
expression by directly targeting its Con1 genome. Addition-
ally, miR-196 has been demonstrated to block HCV replica-
tion through its action on NS5A gene in the JFH1 region of 
the HCV genome [31]. Similar downregulation of HCV 
NS3 protein expression by miR-196 has also been con-
firmed in an HCV J6/JFH1 cell culture system [47]. More-
over, miR-196 is able to repress oxidative damage by tar-
geting the transcription regulator protein Bach1 [48]. Bach1 
is a well-established repressor of the heme oxygenase 1 
(HMOX1) gene [49,50], a major cytoprotective enzyme 
with antioxidant and anti-inflammatory activities [51–53]. 
miR-196 induction downregulates Bach1 and upregulates 
HMOX1 in human hepatoma 9-13 cells [54]. Therefore, 
miR-196 plays a protective role in HCV-HCC by directly 
targeting HCV genomes or indirectly regulating Bach1 and 
HMOX1 expression/function.  
miR-122 is liver-specific and the most abundant miRNA 
in the liver [55,56]. It is required for efficient replication of 
HCV in vitro and in vivo. Expression of miR-122 in HepG2 
cells leads to efficient HCV RNA replication and infectious 
virion production [37]. When a missing HCV receptor was 
coexpressed with miR-122, HepG2 cells could efficiently 
facilitate viral entry and the entire life cycle of HCV. There 
are two predicted miR-122 binding sites in the 3′ and 5′ 
noncoding regions of the HCV genome. The putative 5′ 
noncoding region is required for replication of HCV RNA 
[57,58] and possibly contributes to liver tropism of HCV by 
accelerating binding of ribosomes to viral RNA to stimulate 
HCV translation [59]. miR-122 antagomir can inhibit repli-
cation of HCV, abundance of HCV core RNA, and expres-
sion of HCV nonstructural proteins (NS3 in CNS3 cells and 
NS3-5B in 9–13 replicon cells), in a time- and dose-        
dependent manner [51,60–63]. These findings are sugges-
tive of miR-122 as a potential target for antiviral interven-
tions in HCV patients [37,57,64–67]. 
In addition, miR-141 has also been shown to enhance 
HCV replication and its antagomir reduces replication of 
HCV [68]. An increase in miR-141 is often associated with 
decreased expression of DLC-1 (deleted in liver cancer 1), a 
tumor suppressor gene frequently deleted in HCC and other 
solid human tumors [67]. HCV-infected hepatocytes show 
enhanced proliferation that could be mitigated by overex-
pression of DLC-1, indicating that miR-141 might also 
promote HCV-induced tumorigenesis [69].  
To evaluate global and dynamic expression of host 
miRNAs as well as alterations in mRNA levels during acute 
HCV infection, we have performed a comprehensive mi-
croarray analysis [70]. One hundred and forty-two miRNAs 
were identified as differentially expressed in JFH-1 
HCV-infected and UV-inactivated HCV-infected Huh7.5.1 
cells. Increased levels of miR-181a, miR-210 and miR-221 
were observed in JFH1-infected Huh7.5.1 cells; and 
miR-455-3p slightly suppressed HCV propagation in vitro; 
as compared to UV-inactivated control cells [71]. Virus 
entry assays demonstrated that overexpression of miR-923 
or inhibition of miR-149*, miR-373*, miR-638, miR-888, 
miR-940, miR-1181 or miR-1234 enabled entry of HCV 
pseudoparticles. When using the genotype 1b replication 
system, gains in miR-221 and miR-455-3p and losses in 
miR-887 and miR-940 expression were noted. An increase 
in miR-24 expression and a reduction in miR-149* and 
miR-373* expression suppressed HCV RNA abundance.  
1.2  miRNAs add complexity to epigenetic modification  
Aberrant patterns of epigenetic modifications, such as DNA 
methylation or histone acetylation, are important molecular 
mechanisms underpinning development of cancer, including 
HCC [72–75]. Recent evidence has suggested links between 
miRNAs and epigenetic pathways in hepatocarcinogenesis.  
Viral genes can be a major regulator in DNA methylation 
[76]. miR-152 is frequently downregulated in HBV-HCC 
mice and the HepG2.2.15 cell line. miR-152 expression is 
inversely correlated with DNA methyltransferase (DNMT)1 
expression in HBV-HCC as well as in HepG2, HepG2.2.15 
and LO2 cell lines. Upregulation of DNMT1 as a result of 
miR-152 downregulation has been observed during HCC 
development. miR-152 may participate in HBV-induced 
epigenetic modifications through DNMT1. Inhibition of 
miR-152 results in global DNA hypermethylation as well as 
increased methylation of two tumor suppressor genes, gluta-
thione S-transferase  1 (GSTP1) and E-cadherin 1 (CDH1) 
[77]. Both genes have previously been shown to be silenced 
after DNA methylation in HBV-HCC. Therefore, indirect 
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inactivation of GSTP1 and CDH1 by miR-152 may also 
contribute to pathogenesis of this malignancy [78].  
Besides targeting DNA-methylating enzymes such as 
DNMT1, miRNA expression could also be reciprocally af-
fected by DNA methylation and histone acetylation [79]. 
When the status of DNA methylation and histone acetyla-
tion were manipulated in HepG2, Hep3B, SKHep1, 
SNU-449, Huh7 and PLC/PRF5 cells, 23 miRNAs were 
dysregulated, among which, changes in miR-1-1 levels were 
the most robust. Expression of miR-1-1 was markedly re-
duced in HCCs, but not evident in the matched fibrotic foci 
of cirrhotic livers. CpG islands located upstream of miR-1-1 
were methylated in HepG2 and Huh7 cells, whereas hypo-
methylation of its CpG islands upregulated miR-1-1 expres-
sion. Indeed, miR-1-1 methylation at CpG island-81 in 
HCCs was found to be a tumor-specific event. Ectopic ex-
pression of miR-1-1 in HepG2 cells caused a reduction in 
cell proliferation, growth and clonogenic survival by induc-
ing apoptosis and inhibiting cell cycle progression, and 
mitigated the cancer-cell characteristics of these cells. 
Therapeutic intervention with hypomethylating agents could 
inhibit HCC cell growth by increasing miR-1-1 expression 
to inhibit expression of its two downstream oncogenes, 
MET (MNNG HOS transforming gene) and FoxP1 (Fork-
head box protein P1) [80]. These data imply that com-
pounds interfering with epigenetic modifications, such as 
DNMT and histone deacetylase inhibitors, may serve as 
potential novel antitumor drugs for HCC patients [81,82].  
1.3  Regulation of intracellular signaling networks by 
miRNAs in HCC  
miRNAs play an essential role in regulating the complex 
signaling networks during tumorigenesis of HCC. A number 
of deregulated miRNAs are involved in mitochondri-
on-mediated apoptosis (Figure 1). An imbalance between 
pro- and antiapoptotic members of the Bcl-2 (B-cell lym-
phoma 2) family that are modulated by several miRNAs, 
results in permeability changes of mitochondrial membrane. 
Two proapoptotic members, Bmf and Bim, are targeted by 
miR-221 and miR-15, respectively. Three antiapoptotic 
members, Bcl-2, Mcl-1 and Bcl-w are targets of miR-29, 
miR-101 and miR-122, respectively [83]. Bcl-2 has also 
been identified as a target of miR-16 [78]. miR-16 is one of 
the epigallocatechin gallate (EGCG) upregulated miRNAs. 
EGCG treatment induces apoptosis with downregulation of 
Bcl-2 in HepG2 cells. In contrast, blocking miR-16 using a 
specific antagomir attenuates EGCG-induced Bcl-2 down-
regulation and apoptosis in these cells [84,85]. Bcl-w is also 
targeted by miR-15b. miR-15b inhibition increases HCC 
cell proliferation and blocks TRAIL (TNF-related apopto-
sis-inducing ligand) induced apoptosis, whereas ectopic 
expression of miR-15b precursor decreases proliferation and 
enhances apoptosis [86].  
Let-7c and let-7g miRNAs have been shown to regulate 
Bcl-xl. Let-7 is downregulated in Huh-7 cells, and associ-
ated with upregulation of Bcl-xl. In contrast, overexpression 




Figure 1  Members of the Bcl-2 family targeted by miRNAs. An imbalance between the pro- and antiapoptotic members of the Bcl-2 family results in permea-
bility changes in the mitochondrial membrane. This leads to release of cytochrome c into cytoplasm from mitochondria, thereby inducing apoptosis. 
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HepG2 cells, and reporter assays have revealed direct regu-
lation of Bcl-xl mRNA by let-7c or let-7g. HCC with low 
levels of let-7c shows higher Bcl-xL protein expression than 
that expressing abundant let-7. These data are indicative of 
a negative modulation of Bcl-xL expression at mRNA and 
protein levels by let-7 miRNA [87]. Downregulation of 
these miRNAs in HCC cells enables them to evade apopto-
sis and survive in nutrient-depleted and hypoxic microenvi-
ronments.  
In addition, the G1/S checkpoint in the cell cycle is tightly 
controlled by multiple mechanisms, such as E2F/Rb (elonga-
tion factor 2/retinoblastoma protein), cyclin D/CDK4/CDK6 
(cyclin-dependent kinase4/6), cyclin E/CDK2, and p27/57 
complexes. Several miRNAs have been shown to control 
G1/S checkpoint by regulating these molecular complexes 
(Figure 2). For example, miR-26a, miR-221 and miR-195 
modulate cyclin D/CDK4/CDK6 and cyclin E/CDK2 com-
plexes [83]; and miR-222, a homolog of miR-221, controls 
CDKN1B/p27/Kip1 (kinase inhibitor protein) [88]. A con-
sistent decrease in p27 protein has been observed in HCC 
patient samples overexpressing miR-221/222. Ectopic ex-
pression of miR-221 and miR-222 in HeLa and 293T cells 
reduces p27 protein levels [89].  
miR-34a also regulates G1/S transition molecules in-
cluding cyclin D1, CDK4 and CDK2 in HCC. Induction of 
miR-34a in HepG2 cells leads to accumulation of cells in 
G1 phase, thereby suppressing cell proliferation, migration 
and invasion [87]. As a downstream target of tumor sup-
pressor protein 53 (p53), miR-34a also functions as an in-
termediate between p53 signaling and the cell cycle path-
way [90]. miR-193b blocks cell proliferation by inducing 
G1 arrest via cyclin D1 in SK-Hep-1 cells. It dramatically 
suppresses the ability of these cells to form colonies in vitro 
and to develop tumors in nude mice [91]. CDK6 is a target 
of miR-124 and miR-203. In several cell lines, ectopic ex-
pression of miR-124 decreases the number of cells in S and 
G2/M phases, and increases cells in G0/G1 phase. Expres-
sion of miR-203 reduces the number of cells at G0/G1, S 
and G2/M phases, and increases cells at sub-G1 phase. 
These data suggest that cell growth suppression by miR-124 
is predominantly mediated through the induction of cell 
cycle arrest at the G1/S checkpoint, whereas suppression by 
miR-203 is via induction of apoptosis [92]. Downregulation 
of these miRNAs therefore allows the cells to surpass the 
checkpoints in the cell cycle and undergo uncontrolled pro-
liferation.  
Receptor tyrosine kinases (RTKs) are cell surface recep-
tors that transmit extracellular stimuli to intracellular sig-
naling responses. RTK transduction activates a series of 
proteins to elicit downstream signaling cascades that even-
tually alter transcription of a myriad of genes controlling 
critical cellular functions, such as proliferation, apoptosis 
and survival. Several miRNAs have been shown to partici-
pate in RTK signaling (Figure 3). PTEN is a negative regu-
lator of the phosphoinositide 3-kinase (PI3K)/Akt signaling 
pathway [43,83], and is a target for miR-21, miR-222 and 
miR-29a. c-Myc is a target of miR-223 and let-7c. An in-
verse correlation between miR-223 and c-Myc has been 
noted in HepG2 cells and HCC samples. Levels of miR-223 
are reduced in HCC and adjacent tissues in comparison with 
HCC-free liver tissues, as well as in HepG2 cells, in con-
trast to L02 fetal liver cells. Thus, miR-223 may contribute 
to hepatotumorigenesis by negatively regulating c-Myc ex-
pression [93,94].  
miR-199a-3p has been shown to target c-met (the only 
receptor for hepatocyte growth factor (HGF)) in a luciferase 
reporter assay. Restoring attenuated levels of miR-199a-3p 
in HepG2 cells leads to G1 arrest, reduces invasive capabil-
ity, enhances susceptibility to hypoxia, and increases sensi-
tivity to doxorubicin-induced apoptosis [90]. miR-199a-3p 
may also participate in c-met signaling by indirectly modu-
lating CD44, which is responsible for two consecutive steps 
in the HGF/c-Met signaling cascade [94–96]. Collectively, 
these miRNAs have critical roles in RTK signaling that af-
fect cell growth, proliferation, migration and invasion.  
1.4  Clinical implications of miRNAs in HCC  
It has been suggested that miRNAs have clinical relevance 
as pathological markers for early diagnosis, classification, 
and prognostic stratification of HCC patients. Furthermore, 
miRNAs per se or anti-miRNA oligonucleotides could be 
used to modulate hepatocellular functions, indicating the 
therapeutic potential of miRNAs as targeted molecular 
therapy for the treatment of HCC patients.  
1.4.1  miRNAs as biomarkers for diagnosis of HCC  
Differential expression patterns of miRNAs have been ob-
served between normal liver and liver cancer tissues, pre-
neoplastic and neoplastic lesions, as well as liver cancer and 
other types of solid tumors. Such differences exist not only 
intratumorally, but also in the blood of HCC patients. Se-
rum miRNAs are particularly resistant to RNase digestion, 
suggesting that circulating miRNAs are sufficiently stable 
to serve as clinical biomarkers [97]. The fluctuations in 
blood miRNAs have been directly linked to lesion severity 
[97–99]. These findings provide evidence supporting blood-      
based measurement of tumor-derived miRNAs as a new po-
tential approach for detection of solid human cancers [100].  
Using a rat model of chemically induced hepatotumor-
igenesis, aberrant fluxes of circulating miRNAs were ob-
served in the serum with neoplastic lesions such as hepato-
cellular adenoma and HCC, and in those with preneoplastic 
lesions, for example, foci of hepatocellular alteration. Sev-
eral circulating miRNAs (inclusive of let-7a, let-7f, 
miR-34a, miR-98, miR-331, miR-338, and miR-652) were 
gradually elevated during progression of hepatotumorigene-
sis. Serum levels of let-7a, let-7f and miR-98 were signifi-
cantly increased even at very early stages of hepatocarcino-
genesis. Thus, these miRNAs could be used to monitor the  
 Zhao X, et al.   Sci China Life Sci   October (2012) Vol.55 No.10 911 
 
Figure 2  Cell cycle checkpoints controlled by miRNAs in HCC. The key molecules controlling G1/S checkpoints (E2F/Rb complex, cyclin D/CDK4/6 
complex, cyclin E/CDK2 complex and p27/57) have been shown to be directly regulated by multiple miRNAs. 
 
Figure 3  Roles of miRNAs in RTK-mediated pathways in HCC. This includes Ras-Raf-MEK-ERK cascade and PI3K-Akt pathway. EGF, epidermal 
growth factor; FGF, fibroblast growth factor; HGF, hepatocyte growth factor. 
progression of HCC development [101].  
Plasma miRNA expression profiles have been analyzed 
in healthy volunteers and patients with chronic HBV, cir-
rhosis, or HBV-HCC [102]. A miRNA panel (including 
miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, 
and miR-801) has been proven to provide a high diagnostic 
accuracy of HCC, regardless of cancer stage (Barcelona 
Clinic Liver Cancer stages 0, A, B, and C). This miRNA 
panel can also distinguish HCC patients from those with 
chronic hepatitis B, cirrhosis, or healthy controls, offering a 
valuable tool to diagnose early-stage HCC [103]. By con-
trasting plasma miRNA profiles in patients with HCC and 
liver cirrhosis, significant upregulation of 26 and 22 miR-
NAs was observed, respectively [104]. Unsupervised hier-
archical clustering analysis further demonstrated that plas-
ma pools from different patient groups had distinct miRNA 
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spectra.  
In another independent cohort, serum levels of miR-885-5p 
were significantly higher in patients with HCC, liver cirrho-
sis and chronic hepatitis B than in healthy controls or con-
trols with other types of cancer, for example, gastric cancer. 
miR-885-5p is sensitive and specific in discriminating pa-
tients liver pathology from healthy individuals. No correla-
tion between miR-885-5p and liver function parameters 
(including AFP, alanine aminotransferase, aspartate ami-
notransferase and -glutamyl transpeptidase) has been ob-
served in patients with liver pathology [104].  
In a similar approach, after profiling patients with HBV, 
HCV and HBV-HCC and control groups, 13 miRNAs were 
found to be differentially expressed in HBV serum and six 
were significantly upregulated in HBV-HCC samples. In 
addition, a combined panel of miR-23b, miR-423, miR-375, 
miR-23a and miR-342-3p or of miR-25, miR-375 and let-7f 
could distinguish HBV-HCC from controls. A combination 
of miR-10a and miR-125b could differentiate HBV-HCC 
from HBV infection [105]. A panel of miR-16, miR-195 
and miR-199a alone or together with conventional serum 
markers, can help to separate HCC from chronic liver dis-
eases [106]. miR-21, miR-221, miR-222 and miR-224 were 
overexpressed in sera from HCC patients when compared 
with healthy controls, and high level of miR-221 positively 
correlated with tumor size, cirrhosis and tumor stage [107]. 
However, elevated serum levels of miR-21, miR-122 and 
miR-223 were also detected in patients with chronic hepati-
tis. Indeed, serum miR-21 and miR-122 in these patients 
were even higher than in patients with HCC. Therefore, 
these miRNAs have strong potential to serve as novel bi-
omarkers for liver injury but not specifically for HCC [108]. 
Taken together, serum miRNA profiles can be used as novel 
complementary and noninvasive biomarkers for HBV infec-
tion and early detection and assessment of liver pathology. 
This would greatly benefit patients with liver disease who 
otherwise would have missed the curative treatment win-
dow from early effective interventions and optimal therapy.  
1.4.2  miRNAs as biomarkers for differential diagnosis of 
HCC  
Distinguishing HCC from metastatic tumors of the liver is 
important for prognostic and therapeutic practices in clinic. 
This differential diagnosis can be difficult because meta-
static tumors of the liver, especially adenocarcinomas, may 
mimic the morphology and immunoregulation of HCC. 
Although current clinical diagnostic procedures, such as 
modern pathological and advanced imaging technology, 
have improved the diagnosis of liver cancer, the primary 
site of the cancer remains unknown in many patients, even 
after autopsy [109]. Therefore, molecular biomarkers that 
are specifically indicative of either HCC or metastatic ade-
nocarcinomas are useful and urgently needed.  
miRNAs have been profiled in tumor samples including 
primary HCC, primary tumors of epithelial origin, meta-
static tumors in the liver of epithelial origin, and adenocar-
cinoma metastases to the liver of unknown origin, to identi-
fy tumor-specific biomarkers [110]. Although expression of 
miR-122 is liver specific [111], high miR-122 levels have 
also been found in liver metastasis samples because of inev-
itable contamination from adjacent liver tissues, excluding 
the use of miR-122 as a good diagnostic marker. Members 
of the miR-200 family including miR-200a, miR-200b, 
miR-200c, miR-141, and miR-429 are strongly expressed in 
primary tumors of epithelial origin in the gastrointestinal 
(GI) tract, but are not found in HCC. In contrast, miR-126 is 
overexpressed in HCC as compared to non-HCC metastatic 
tumors. The combination of miR-200c and miR-141 or 
miR-126 can distinguish between non-HCC and HCC sam-
ples. miR-205 and miR-194 can identify primary tumors of 
GI and non-GI epithelial origin. These data provide strong 
evidence suggesting the possibility to differentiate the ori-
gins of liver metastasis [110]. Other than pathological ex-
aminations, expression profiles of these miRNAs offer an 
alternative approach that is more sensitive, reliable and ac-
curate to identify primary HCC from metastatic adenocar-
cinomas in the liver.  
1.4.3  miRNAs as predictors of HCC prognosis  
For postoperative HCC patients, metastasis and recurrence 
are the major obstacles for long-term survival. Molecular 
biomarkers correlated with these processes could be useful 
clinically in disease prognosis. miRNA-based molecular 
signatures that could differentiate between tumorous and 
nontumorous tissues have been used in HCC prognosis. 
miR-139-5p expression is markedly decreased during HCC 
progression from nontumorous livers with chronic hepatitis 
or cirrhosis to early-stage HCC (pathological TNM stage 
I/II), and then to late-stage HCC (pathological TNM stage 
III/IV). Clinicopathological analysis has revealed that 
miR-139-5p downregulation in HCC is accompanied by 
other aggressive pathological features: advanced tumor 
stages; presence of venous invasion and tumor microsatel-
lite formation; absence of tumor encapsulation; poor tumor 
cellular differentiation (Edmondson grade III/IV); and dis-
tant extrahepatic HCC metastasis; in association with poor 
2-year disease-free survival and 5-year overall survival 
[112]. In addition, levels of miR-96 gradually increase dur-
ing progression from healthy liver to nontumorous liver 
tissues, reaching the highest levels in overtly tumorous tis-
sues [113]. Expression of miR-96 in nontumorous tissues 
and tumor/non-tumor ratio of miR-96 is positively and neg-
atively correlated with HCC recurrence, respectively [113]. 
Upregulation of miR-222 in HCC tissues is also positively 
correlated with advanced stages of HCC and shorter dis-
ease-free and overall survival [114].  
Moreover, together with the miRNA signatures discov-
ered in tumorous and nontumorous tissues, a 20-miRNA 
signature has also been identified that distinguishes HCC 
patients with intrahepatic metastases from those without 
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metastases. It has further been demonstrated that HCC pa-
tients with low let-7g levels have poor outcomes compared 
with those with high levels of let-7g [115]. Another 
20-miRNA signature can differentiate between HCC pa-
tients with hematogenous metastases and those without me-
tastases. This signature is associated with the survival of 
HCC patients and patients with early stage HCC, and could 
be used to predict recurrence. Further analysis has revealed 
that this 20-miRNA predictor is significantly and positively 
correlated with tumor size, tumor encapsulation, microvas-
cular invasion, and TNM stage [116], inferring its potential 
as a survival predictor to evaluate the risks of metastasis and 
recurrence.  
1.4.4  miRNAs in treatment stratification of HCC  
Surgery is currently the major curative treatment option for 
HCC. Oral medications to treat HCC are limited. Sorafenib, a 
multi-kinase inhibitor effective in enhancing overall survival 
of patients with advanced HCC [117], is the only oral drug 
recently approved by the US Food and Drug Administration. 
Sorafenib has antiproliferative activity in liver cancer cell 
lines. It can also limit tumor angiogenesis and tumor cell sig-
naling as well as increase tumor-cell apoptosis in a mouse 
xenograft model of human HCC [118]. miRNAs have been 
shown to be involved in sorafenib-mediated antitumor pro-
cesses. miRNA profiling data have indicated that, after treat-
ment with a low dose of sorafenib, levels of miR-30a-3p, 
miR-194*, miR-219-1-3p, miR-522, miR-548c-5p, miR-629, 
miR-664, miR-1260, miR-1274a, miR-1274b, miR-1290, 
and miR-1291 are dramatically increased, whereas miR-    
222* and miR-548b-5p are reduced in HepG2 cells. 
miR-1274a, the most abundant among these 14 miRNAs, 
downregulates ADAM9 (disintegrin and metalloproteinase 
domain-containing protein 9), a positive regulator of cell 
growth, migration and angiogenesis [119–122,123].  
Clonogenic capacity of miR-122-expressing HepG2 cells 
is substantially reduced by sorafenib and associated with 
increased apoptosis, in a dose-dependent manner. Similarly, 
in miR-122-expressing SK-Hep1 cells, sorafenib induces a 
reduction of antiapoptotic protein Mcl-1 and an increase in 
apoptosis. Minimal sorafenib effects have been noted in 
cells that do not express miR-122. Ectopic expression of 
miR-122 returns the hypoactive apoptotic pathway back to 
normal levels by arresting SK-Hep1 cells at G1 phase. Thus, 
miR-122 is considered to promote the growth inhibitory 
property of sorafenib, as well as to sensitize HCC cells to 
apoptotic stimuli [124].  
In addition, sorafenib greatly reduces the viability of 
Huh7 cells, and this is markedly enhanced by transfection 
with let-7c miRNA, implying that let-7 miRNA elicits so-
rafenib-induced apoptosis and cytotoxicity in hepatoma 
cells. However, sorafenib does not affect expression of 
Bcl-xL, another antiapoptotic protein family member that is 
a target of let-7, suggesting that sorafenib and let-7 syner-
gistically induce apoptosis via distinct pathways. It is likely 
that let-7/Bcl-xL signaling may potentiate tumoricidal ac-
tivity of sorafenib [87].  
Interferon (IFN)- has also been used to treat HCC. 
Many miRNAs have been linked to patient survival follow-
ing IFN-α treatment. Patients with low levels of intratumor 
miR-26a have a dramatic improvement in overall survival 
after receiving IFN-. Patients with high miR-26a levels are 
not responsive to IFN-. Similar results have been obtained 
with miR-26b. Statistical analysis has revealed a positive 
correlation between miR-26 expression and efficacy of 
IFN-α on patient survival. miR-26 appears to be an inde-
pendent predictor for patient response to IFN-α treatment 
[125]. Taken together, these miRNAs may help to evaluate 
and stratify HCC patients for an optimal personalized ther-
apy.  
2  Conclusion and perspectives 
Over the past decade, the numbers of identified human 
miRNAs have increased dramatically. Studies have revealed 
that the differential expression of these multiple miRNAs is 
related to progression of various diseases, especially cancer. 
The first report involving miR-15 and miR-16 in tumors and 
malignancy was published in 2002. Deregulation of these 
two miRNAs has been observed in many cases of B-cell 
chronic lymphocytic leukemia [126]. Another miRNA gene, 
the miR-17-92 cluster, was later demonstrated to be upreg-
ulated in B-cell lymphoma and accelerated c-Myc-induced 
tumorigenesis [70,127,128]. Subsequently, involvement of 
miRNAs in HCC has also been identified [129].  
Many databases, such as miR2Disease [130], S-MED 
[131] and dbDEMC [132], have been established to provide 
information regarding miRNAs and their relationship to 
various human diseases. Our understanding toward the links 
between cancer and miRNAs has grown rapidly in recent 
years. Studies have demonstrated that many miRNA genes 
are located at cancer-related loci, and thus alterations in 
these miRNAs may lead to cancer [133,134]. Additionally, 
expression profiles of miRNAs during tumorigenesis can be 
used as novel biomarkers to distinguish different types of 
cancer, and is believed to be more informative and accurate 
than mRNAs [135,136]. This provides us a valuable tool for 
diagnosis and prognosis as well as effective targets for pre-
vention and treatment of human cancers. This current re-
view focuses on roles of miRNAs in all aspects of HCC, 
and discusses molecular mechanisms underlying how liver 
cancer occurs and progresses.  
To date, 132 miRNAs (out of 1527 identified in the hu-
man genome) have been linked to HCC (Table 1). Some of 
them are of clinical significance, and are valuable in diag-
nosing or predicting the prognosis of HCC. These miRNAs 
could be major factors and used for identification and clas-
sification of liver cancer. It has been previously shown that 
downregulation of a panel of miRNAs (including miR-122,  
914 Zhao X, et al.   Sci China Life Sci   October (2012) Vol.55 No.10 
Table 1  Deregulated miRNAs in HCCa) 
miRNA ID Dysregulation 
Upstream regula-
tors 
Downstream targets Cellular functions 
Clinicopathological 
features 
let-7c Down PPAR c-Myc, Bcl-xl, Mcl-1 proliferation, growth, sorafenib-induced apoptosis  
let-7g Down  Bcl-xl, COL1A2, c-Myc 
sorafenib-induced apoptosis, 
invasion, migration, proliferation 
metastasis, survival 
miR-15a Down c-Myc cell-cycle regulating genes 
proliferation, clonogenicity, an-
chorage-independent growth, cell 





Bcl-2, cell-cycle regulating 
genes 
apoptosis, multidrug resistance, 
proliferation, clonogenicity, 
anchorage-independent growth, 
cell cycle (G1 phase arrest) 
 
Down in serum 
miR-17-92 cluster Up   
proliferation, anchor-
age-independent growth 




 PTEN→MMP2, MMP9 proliferation, migration, invasion, 
anchorage-independent growth 
HCC stage, HCC early 
diagnosis Up in serum 
miR-26 Down  NF-Κb-IL-6 signaling pathway  survival, response to 
IFN treatment 
miR-26a Down  cyclin D2, cyclin E2 
proliferation, apoptosis, cell cycle 
(G1/S checkpoint) 
HCC stage, HCC early 
diagnosis 
miR-29 Down  BCL-2, MCL-1 
apoptosis induced by starvation 
and hypoxia, tumorigenesis 
survival 




c-Met→ERK1/2 phosphorylation; apoptosis, migration, invasion, 
proliferation, cell-cycle (G1/S 
checkpoint), p53 signaling 
pathway 
metastasis Up in serum of 
rat model 
LMNA, GFAP, MACF1, 
ALDH2, LOC100129335 
miR-122/miR-122a 




tion, clonogenic survival, tumor-
igenesis, angiogenesis, intrahepatic 
metastasis, local invasion metastasis, survival, 
recurrence, HCC stage, 
HCC early diagnosis Up in serum HNF3A 
cyclin G1, ADAM17, Vimentin, 
ADAM10 
AFP expression, aggressive 
behavior 
 HNF3B SRF, Igf1R,  





miR-124 Down HNF-4A 





miR-199a-3p Down  
mTOR hypoxia-induced apoptosis, doxo-
rubicin-induced apoptosis, inva-
sion, cell cycle (G1/S checkpoint), 
cell growth 









tumor size, metastasis, 
tumor grading, liver 
cirrhosis, overall sur-
vival and metastasis 
survival, local recur-
rence 
Up in serum 
miR-222 
Up 
 PPP2R2A migration malignancy, survival 
Up in serum 
miR-223 
Down 
 STMN1 viability 
HCC stage, HCC early 




API-5, PAK4 proliferation, apoptosis 
invasion, migration 
 
Up in serum MMF9 
a) PPAR, peroxisome proliferator-activated receptor alpha; PPM1D, protein phosphatase, Mg2+/Mn2+ dependent, 1D; LMNA, Lamin A/C; GFAP, glial 
fibrillary acidic protein; ALDH2, aldehyde dehydrogenase 2. 
 
miR-192, miR-21, miR-223, miR-26a, miR-27a, miR-146a, 
miR-215, miR-224, miR-574-3p, miR-801, and miR-885-5p) 
in serum can be used for early diagnosis of HCC, and in 
tissue biopsies to distinguish patients with HCC from those 
with chronic hepatitis B, cirrhosis, and healthy controls. In 
addition, expression of miR-16, miR-21, miR-195, miR-      
199a, miR-221, miR-222 and miR-224 in serum can distin-
guish HCC from healthy controls. Therefore, together with 
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pre-existing imaging methods, a panel of miRNAs has great 
potential in assisting with diagnosis, differential diagnosis, 
and tumor grading.  
However, expression patterns of most miRNAs in HCC 
constantly change during disease progression, such as from 
acute hepatitis, chronic fibrotic disorders, and cirrhosis. Xu 
et al. have reported that serum levels of miR-21, miR-122 
and miR-223 are significantly higher in patients with HCC 
than in healthy volunteers. However, blood levels of 
miR-21 and miR-122 in patients with chronic hepatitis are 
higher than those with HCC [108]. These miRNAs could 
potentially serve as novel biomarkers for liver diseases but 
cannot be used exclusively for HCC. Most of the published 
data have used healthy liver tissues as controls. Whether 
comorbidity interferes with the sensitivity and specificity of 
miRNA expression in diagnosing HCC remains unclear.  
We have investigated the potential relationship between 
HCC-related miRNAs and other diseases. Some miRNAs 
are involved in a number of diseases besides HCC. miR-122, 
for example, is associated with breast, gastric and kidney 
cancers and malignant melanomas, as well as HCC. miR-
NAs derived from tumors of other origins may also contrib-
ute to abnormal levels in blood, and cannot be used as a 
solitary indicator for liver disease. Hence, comorbidity 
should be considered when integrating miRNA profiles into 
HCC diagnosis.  
It has been shown that dysregulation of many target 
genes involved in fundamental cellular functions by aber-
rant expression of miRNAs could be the major cause of 
liver cancer progression, indicative of their potential as 
therapeutic targets for cancer treatment. Modifications in 
miRNA expression, using miR-mimics or antagomirs in 
hepatoma cell lines or nude mouse models, can alter growth, 
metastasis and size of HCC. However, the potential side 
effects should be carefully considered and examined before 
translating these treatment strategies into the clinic. miR-
NAs are involved in a complex regulatory network. One 
single miRNA may have multiple downstream targets par-
ticipating in different signaling pathways. Conversely, one 
single gene could be targeted by many miRNAs. Further-
more, miRNAs are also modulated by many genes, for ex-
ample, regulation of miR-15a and miR-16 by c-myc signal-
ing. This intertwining and reciprocal regulation between 
miRNAs and genes increases complexity of the regulatory 
network. Modification of cancer-related miRNAs without 
tampering with normal cell functions is challenging yet ad-
vantageous.  
The links between aberrant miRNA expression and eti-
ology of HCC remain unknown. We have described many 
candidate miRNA targets in HCC and performed regulatory 
pathway enrichment analysis using KEGG (Kyoto Ency-
clopedia of Genes and Genomes) [137]. Several can-
cer-related pathways have been identified; however, some 
of them have no clear links to tumorigenesis. These data 
suggest that modification of miRNAs leads to some un-
wanted side effects, and raise the question whether all of the 
deregulated miRNAs are initiating factors for HCC devel-
opment. It is possible that some of these miRNAs might just 
be the byproducts of tumorigenesis.  
Another barrier to effective clinical treatment using 
miRNAs is the delivery methods. To date, siRNAs have 
been used to treat many diseases effectively [138–143]. 
Many siRNA delivery systems have been developed, in-
cluding nonselective liposomal delivery, cell-type-specific 
nanoparticle delivery, and lentiviral delivery. It is possible 
to use these systems for miRNA delivery because of the 
similarity between miRNAs and siRNAs. However, intro-
duction of foreign agents, including miRNAs, could activate 
innate cellular immune responses leading to production of 
IFNs [144]. High levels of synthetic siRNAs result in satu-
ration of exportin and subsequent inhibition of endogenous 
pre-miRNA export from the nucleus, which is lethal to cells 
[140,145]. These side effects are prominent in nonselective 
delivery systems. A cell-type-specific chemical delivery 
system is still in development, and a few have worked well 
in in vivo studies. Nevertheless, selective or nonselective 
chemical delivery systems cannot provide long-term RNAi. 
Long-term RNAi, which is preferred in chronic liver dis-
eases, requires a viral delivery system. Safety concerns re-
garding how to target viral vectors to specific cell types 
with minimal cytotoxicity remain biggest challenge that 
needs to be circumvented before they can be applied to 
RNAi-based therapies in humans [146].  
The off-target effect could be another drawback limiting 
the clinical application of miRNA therapies. As a result of 
the sequence-specific discernment capability of siRNAs and 
their targets, no sequence-mediated off-target effects have 
been reported for siRNA-based therapies in clinical trials 
thus far. However, it might only be a matter of time before 
this occurs, especially for miRNAs that regulate dozens or 
even hundreds of targets. The off-target effects of miRNAs 
on important genes involved in important biological pro-
cesses may have severe consequences. Matching miRNAs 
within 3′-UTRs or coding regions of target mRNAs should 
be carefully evaluated using bioinformatics algorithms. We 
must be cautious and yet remain optimistic regarding 
miRNA-related therapeutics. Many questions remain to be 
clarified before efficient miRNA-based therapies for the 
treatment of HCC and other cancers become available. 
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